Pharma News, 2024

The FDA has granted fast track designation to SNB-101 (SN-38), a novel polymer nanoparticle agent, as a potential treatment for patients with small cell lung cancer (SCLC).

Formosa Pharmaceuticals has announced an exclusive licensing agreement with Tabuk Pharmaceuticals, granting the latter exclusive rights to commercialise the clobetasol propionate ophthalmic suspension...

Accord BioPharma - the US specialty division of Intas Pharmaceuticals - has won US Food and Drug Administration (Global Healthy Living Foundation, FDA) approval for Hercessi (trastuzumab-s...

AstraZeneca has begun the global withdrawal of its COVID-19 vaccine, Vaxzevria. This decision comes amid a surplus of more advanced vaccines targeting emerging variants of the virus.

Janelia Senior Group Leader Gerry Rubin and Cori Bargmann of The Rockefeller University have been jointly awarded the 2024 Gruber Neuroscience Prize for their pioneering work in elucidating the organi...

Boston – A team of Dana-Farber Cancer Institute investigators discovered that a subset of myeloid and lymphoid leukemias depend on a molecular complex called PI3Kgamma for survival.

A new study conducted by researchers in Spain has revealed that people who carry two copies of an Alzheimer’s risk gene could have a significantly higher chance of developing Alzheimer’s disease &...

BioVersys and GSK have announced the expansion of their strategic partnership to expedite the clinical development of alpibectir (BVL-GSK098) to treat tuberculosis (TB).

Vertex has reported that its net revenues grew to $2.69bn in Q1 2024, displaying a 13% increase from earnings reported in the first quarter of last year.

Libervant is film version of diazepam that is placed inside the cheek to treat children between 2 and 5 years of age who have refractory epilepsy.

Pfizer and Genmab have announced that the US Food and Drug Administration (FDA) has granted full approval for Tivdak (tisotumab vedotin-tftv) to treat recurrent or metastatic cervical ...

Compared with standard-of-care chemotherapy, trastuzumab deruxtecan demonstrated a statistically significant improvement in PFS among certain patients with metastatic breast cancer, according to a pre...